Beta test rollout. This site is in community QA — please send feature requests, bug reports and data corrections on the Feedback page or on GitHub.

Home
    Disclaimer
    25B-NBOH molecular structure

    25B-NBOH Stats & Data

    Nboh-2c-b 2c-b-nboh 25bnboh nboh-2cb 2cb-nboh
    NPS DataHub
    MW366.25
    FormulaC17H20BrNO3
    CAS1335331-46-8
    IUPAC2-[[2-(4-bromo-2,5-dimethoxyphenyl)ethylamino]methyl]phenol
    SMILESCOc1cc(CCNCc2ccccc2O)c(OC)cc1Br
    InChIKeyRSUNJYKZRKIBNB-UHFFFAOYSA-N
    Phenethylamines
    Chemical Class N-benzylphenethylamine
    Psychoactive Class Psychedelic

    Receptor Profile

    Receptor Actions

    Agonists
    5-HT2A receptor agonist (potent)
    5-HT2C receptor agonist

    History & Culture

    25B-NBOH was first synthesized and documented in 2011 by Martin Hansen at the University of Copenhagen. The compound is a structural derivative of the phenethylamine psychedelic 2C-B, belonging to the broader family of N-benzyl phenethylamines and sharing close structural relationships with the 25x-NBOMe series of compounds. Prior to its synthesis, 25B-NBOH had no documented history of human consumption. It emerged on the online designer drug market in 2011, the same year it was first characterized, appearing for sale without any established safety profile or prior research into its effects in humans. The compound remains one of the lesser-studied members of the NBOx class, with its availability driven primarily by the grey market rather than any scientific or therapeutic interest.

    Toxicity

    PsychonautWiki

    25B-NBOH is a relatively new substance, and little is known about its toxicity or interaction with other substances. It is assumed to pose similar acute health risks as 25B-NBOMe and other members of 25x-NBOMe series. The LD50 has not yet been determined although it is likely to be potentially fatal at heavy dosages. 25B-NBOH's extreme potency means it should not be insufflated (snorted) as this method of administration has been associated with many deaths and hospitalizations with closely related members of the 25x-NBOMe series.

    Effect Profile

    Curated + 4 Reports
    Psychedelic 8.4

    Strong visuals, auditory effects, and headspace with strong body load

    Visual Intensity×3
    10
    Headspace Depth×3
    9
    Auditory Effects×1
    10
    Body Load / Somatic Effects×1
    10
    Based on reports from:

    Tolerance & Pharmacokinetics

    drugs.wiki
    Half-Life
    unknown
    Addiction Potential
    Not habit-forming

    Tolerance Decay

    Full tolerance 12h Half tolerance 7d Baseline ~14d

    Immediate acute tolerance develops after dosing; cross‑tolerance with other 5‑HT2A agonists is expected. Anecdotal reports suggest tolerance may persist ~1–2 weeks depending on dose and individual variability. Data quality is limited and primarily anecdotal.

    Cross-Tolerances

    LSD/lysergamides
    Other phenethylamine psychedelics (e.g., 2C‑B/DOx)
    Other NBOH/NBOMe

    Experience Report Analysis

    Erowid
    6 Reports
    4 Single-substance
    2018–2022 Date Range
    6 With Age Data
    5 Effects Detected

    Demographics

    Gender Distribution

    Too few reports for a chart: gender is known from 6 reports, and a split is drawn only from 20 reports or more. Counts are shown instead. Why 20?

    • Male 6 of 6

    Age Distribution

    Reports Over Time

    Effect Analysis

    Erowid

    Effects aggregated from 4 experience reports (4 single-substance Erowid)

    4 Reports
    5 Effects Detected
    4 Positive
    1 Adverse
    0 Neutral

    Effect Sentiment Distribution

    Confidence Distribution

    Each bar is the share of reports mentioning the effect; its whisker, and the band on the rows below, is the 95% interval: where the share could plausibly be with other reports of the same kind.

    Too few reports for bars: these effects come from 4 single-substance Erowid reports, and a bar is drawn only from 20 reports or more. With fewer, a percentage cannot tell a common effect from a rare one. Counts are shown instead. Why 20?

    Positive Effects 4

    Visual Distortions 4 of 4 70%
    Color Enhancement 4 of 4 70%
    Introspection 3 of 4 70%
    Empathy 3 of 4 70%

    Adverse Effects 1

    Anxiety 3 of 4 70%

    Form / Preparation

    Most common forms and preparations, as a share of the 4 reports that give one

    Too few reports for bars: these forms come from 4 reports, and a bar is drawn only from 20 reports or more. With fewer, a percentage cannot tell a common effect from a rare one. Counts are shown instead. Why 20?

    • Blotter / Tab 3 of 4

    Legal Status

    Country Status Notes
    Brazil Controlled (Portaria SVS/MS nº 344) Added to the controlled substances list under Portaria SVS/MS nº 344 on December 10, 2018. Possession, distribution, and use are prohibited under Brazilian law.
    Germany Controlled (NpSG) Regulated under the Neue-psychoaktive-Stoffe-Gesetz (New Psychoactive Substances Act) since November 26, 2016. Production and import with intent to distribute, administration to others, and commercial trading are criminally punishable. Personal possession is prohibited but not subject to criminal penalty.
    Sweden Schedule I (Narcotic) Listed under Schedule I of the Narcotic Drugs Punishments Act, a classification for substances without recognized medical use. The scheduling was published by the Medical Products Agency in regulation HSLF-FS 2015:35.
    Switzerland Controlled (Verzeichnis E) Regulated as a defined derivative of N-benzylphenethylamine under Verzeichnis E, point 131 of Swiss controlled substances legislation. An exemption exists permitting use for scientific or industrial purposes.
    United Kingdom Class A Classified as a Class A controlled substance under the Misuse of Drugs Act 1971 through the N-benzylphenethylamine catch-all provision. Class A substances carry the most severe penalties under UK drug law.
    United States Unscheduled Not explicitly scheduled under the Controlled Substances Act. However, possession or distribution intended for human consumption may be prosecuted under the Federal Analogue Act due to structural and pharmacological similarities to the Schedule I substance 25B-NBOMe.

    Harm Reduction

    drugs.wiki

    25B‑NBOH is active in the microgram range; inaccurate measurement (e.g., eyeballing powder) greatly increases overdose risk and should be avoided. NBx compounds (NBOH/NBOMe) have produced severe adverse effects including vasoconstriction, agitation, seizures, hyperthermia, and rhabdomyolysis in clinical case series; medical evaluation is warranted for symptoms like chest pain, blue/cold extremities, prolonged confusion, or seizure. Buccal/sublingual absorption is the primary active route; swallowing reduces effects variably, and redosing during a slow onset has led to accidental overdoses with related NBx. 25B‑NBOH has been mis-sold as ‘LSD’ (including in powder form, which is atypical for LSD); use multi-reagent testing and drug checking where available. Ehrlich reagent turns purple for indole lysergamides (e.g., LSD) but shows no color with NBOH/NBOMe; Hofmann/Marquis patterns can add context—however, reagent tests are screening tools, not definitive IDs. Bitter taste and localized oral numbing are commonly reported with NBx, but taste is not a reliable identification method and should not replace testing. Strong stimulatory combinations (e.g., with amphetamines or cocaine) elevate risks of hypertension and dangerous vasoconstriction beyond either drug alone. Tramadol lowers seizure threshold and has been repeatedly associated with seizures when combined with serotonergic psychedelics; avoid. Lithium has many consistent reports of severe adverse reactions, including seizures, when combined with classical psychedelics; given the similar 5‑HT2A agonism of NBOH compounds, this combination should be considered high‑risk. SSRIs often blunt psychedelic effects via receptor downregulation; they are not reliable ‘safety buffers’ and may complicate responses—avoid intentional mixing. Cannabis can unpredictably potentiate psychedelics and anxiety; titrate cautiously or avoid. Tolerance to 5‑HT2A agonists can be pronounced for days; allow at least 1–2 weeks between strong psychedelic sessions to reduce the urge to escalate dose. Seek immediate care for signs of hyperthermia (hot, confused, profuse sweating), chest pain, severe headache, seizure activity, or new neurologic deficits.

    References

    ← Back to 25B-NBOH